Literature DB >> 11914304

Effects of adjusting for censoring on meta-analyses of time-to-event outcomes.

Claire L Vale1, Jayne F Tierney, Lesley A Stewart.   

Abstract

BACKGROUND: Systematic reviews of published time-to-event outcomes commonly rely on calculating odds ratios (OR) at fixed points in time and where actual numbers at risk are not presented. These estimates are usually based on the total numbers included in the published analysis and take no account of censoring. We have assessed the impact of adjusting for censoring on weighting, estimates and statistical heterogeneity of meta-analyses in cancer.
METHODS: Meta-analyses of survival data for five meta-analyses of published trials in cancer were conducted. The OR and associated statistics were calculated based on unadjusted total numbers of participants and events. These were compared with calculations that first adjusted the numbers at risk for censoring using a simple model.
RESULTS: Pooled OR were changed in 17/24 cases. On average, there was a 2.6% difference between the adjusted and unadjusted OR. Confidence intervals were frequently wider for the adjusted OR. Adjusting also reduced weighting of individual trials with immature follow-up. In 18/24 cases, adjusting reduced statistical heterogeneity and affected the associated P-values.
CONCLUSIONS: Reviewers conducting meta-analyses of published time-to-event data where actual numbers at risk are not available should adjust the numbers at risk, estimated from total numbers analysed, to account for immature data and censoring.

Entities:  

Mesh:

Year:  2002        PMID: 11914304     DOI: 10.1093/ije/31.1.107

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  8 in total

1.  Cochrane Reviews: new blocks on the kids.

Authors:  I Shrier
Journal:  Br J Sports Med       Date:  2003-12       Impact factor: 13.800

2.  Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.

Authors:  R D Riley; K R Abrams; A J Sutton; P C Lambert; D R Jones; D Heney; S A Burchill
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

3.  Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.

Authors:  Eugeniu Banu; Adela Banu; Andrei Fodor; Bruno Landi; Philippe Rougier; Gilles Chatellier; Jean-Marie Andrieu; Stephane Oudard
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jorge Henrique Bento de Sousa; Igor Lepski Calil; Francisco Tustumi; Douglas da Cunha Khalil; Guilherme Eduardo Gonçalves Felga; Rafael Antonio de Arruda Pecora; Marcio Dias de Almeida
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 5.  Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma.

Authors:  Ching-Sheng Hsu; You-Chen Chao; Hans Hsienhong Lin; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Sci Rep       Date:  2015-05-12       Impact factor: 4.379

6.  A pooled analysis of mesenchymal stem cell-based therapy for liver disease.

Authors:  Lu Zhao; Shanquan Chen; Xiaowei Shi; Hongcui Cao; Lanjuan Li
Journal:  Stem Cell Res Ther       Date:  2018-03-21       Impact factor: 6.832

7.  Efficacy of early use of remdesivir: a systematic review of subgroup analysis.

Authors:  M D Gil-Sierra; M P Briceño-Casado; E J Alegre-Del Rey; M Sánchez-Hidalgo
Journal:  Rev Esp Quimioter       Date:  2022-03-17       Impact factor: 2.515

8.  A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.

Authors:  Andrew F Irvine; Sara Waise; Edward W Green; Beth Stuart
Journal:  BMC Med Res Methodol       Date:  2020-10-30       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.